Immunome, Inc. (IMNM) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.0x

Market Cap

$3.04B

MomentumView details →

1D Return

−1.47%

YTD Return

+25.44%

RSI (14)

51.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.0x

Market Cap

$3.04B

RSI (14)

51.8

MomentumView details →

1D Return

−1.47%

YTD Return

+25.44%

SummaryUpdated Jun 1, 2026

Immunome, Inc. (NASDAQ:IMNM) is a biopharmaceutical company founded in 2006 and headquartered in Exton, Pennsylvania. The company went public in October 2020 and focuses on discovering and developing antibody-based therapeutics for treating cancer and infectious diseases. Immunome leverages its proprietary antibody discovery platform to identify novel therapeutic targets and develop treatments that harness the immune system's power to fight disease.

Ask drillr about Immunome, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−48.43%

ROA (TTM)

−44.98%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+17.53%

FCF YoY

−17.68%

Revenue CAGR 3Y

−29.63%

EPS CAGR 3Y

+51.40%

EBITDA YoY

−38.17%

EarningsView details →

EPS (Actual)

−$0.65

EPS Surprise

−26.51%

Beats (12Q)

4/12

Next Q EPS Est

−$0.60

Avg Surprise (4Q)

−8.98%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

15.08x

Quick Ratio

15.08x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−254.32M

Op. CF (TTM)

−208.79M

Next earningsNov 5, 2026 →

Latest newsMore news →

Immunome dosed the first patient in a Phase 1 trial of IM-3050, an FAP-targeted radioligand therapy, for advanced solid tumors.46d ago

Immunome announced that the U.S. FDA accepted its New Drug Application for varegacestat for the treatment of adults with desmoid tumors.58d ago

Similar companies

Disc Medicine, Inc.IRON NewAmsterdam Pharma Company N.V.NAMS 蔚蓝生物603739.SH Beam Therapeutics Inc.BEAM Arcutis Biotherapeutics, Inc.ARQT 凯因科技688687.SH Find similar companies →

Latest newsMore news →

Immunome dosed the first patient in a Phase 1 trial of IM-3050, an FAP-targeted radioligand therapy, for advanced solid tumors.46d ago Immunome announced that the U.S. FDA accepted its New Drug Application for varegacestat for the treatment of adults with desmoid tumors.58d ago